Oculis Holding AG (OCS) Income towards Parent Company (2022 - 2026)
Oculis Holding AG (OCS) posted quarterly Income towards Parent Company of -$37.1 million for Q1 2026, little changed year-over-year from -$37.3 million in Q1 2025, and down 151.01% quarter-over-quarter from $72.7 million in Q4 2025.
Analysis
Oculis Holding AG (OCS) Income towards Parent Company (2022 - 2026) Analysis & Trends
Oculis Holding AG's Income towards Parent Company history runs 5 years deep, the most recent figure standing at -$37.1 million for Q1 2026.
- In Q1 2026, Income towards Parent Company changed 0.46% year-over-year to -$37.1 million; the TTM figure through Mar 2026 stood at -$21.0 billion (up 9.94% YoY), while the FY2025 annual figure was -$119.8 million, down 22.42% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$37.1 million, down from $72.7 million in the prior quarter.
- The five-year high for Income towards Parent Company was $72.7 million in Q4 2025, with the low at -$23.3 billion in Q3 2024.
- The 5-year median for Income towards Parent Company is -$21.5 million (2023), against an average of -$2.8 billion.
- The sharpest annual moves came in 2024 and 2025: Income towards Parent Company sank 116344.35% in 2024, then jumped 318.67% in 2025.
- Oculis Holding AG's Income towards Parent Company stood at -$9.6 million in 2022, then tumbled by 47.68% to -$14.1 million in 2023, then plunged by 135.51% to -$33.3 million in 2024, then surged by 318.67% to $72.7 million in 2025, then tumbled by 151.01% to -$37.1 million in 2026.
- Business Quant data shows OCS's Income towards Parent Company at -$37.1 million in Q1 2026, $72.7 million in Q4 2025, and -$21.0 billion in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Oculis Holding AG | 634.75 Mn | 345.87 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -202.44 |
| Mar 31, 2026 | -625.73 |
| Dec 31, 2025 | -525.49 |
| Sep 30, 2025 | -400.04 |
| Jun 30, 2025 | -591.87 |
| Mar 31, 2025 | -767.45 |
| Dec 31, 2024 | -764.82 |
| Sep 30, 2024 | -554.02 |
| Jun 30, 2024 | -563.95 |
| Mar 31, 2024 | -504.10 |
| Dec 31, 2023 | -383.30 |
| Sep 30, 2023 | -543.43 |
| Jun 30, 2023 | -422.63 |
| Mar 31, 2023 | -3,859.75 |
| Dec 31, 2022 | -2,709.24 |
| Sep 30, 2022 | -2,982.12 |
| Jun 30, 2022 | -3,779.39 |